Literature DB >> 24140051

A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains.

Tracey M Doyle1, Changgui Li, Doris J Bucher, Anwar M Hashem, Gary Van Domselaar, Junzhi Wang, Aaron Farnsworth, Yi-Min She, Terry Cyr, Runtao He, Earl G Brown, Aeron C Hurt, Xuguang Li.   

Abstract

All influenza viral neuraminidases (NA) of both type A and B viruses have only one universally conserved sequence located between amino acids 222-230. A monoclonal antibody against this region has been previously reported to provide broad inhibition against all nine subtypes of influenza A NA; yet its inhibitory effect against influenza B viral NA remained unknown. Here, we report that the monoclonal antibody provides a broad inhibition against various strains of influenza B viruses of both Victoria and Yamagata genetic lineage. Moreover, the growth and NA enzymatic activity of two drug resistant influenza B strains (E117D and D197E) are also inhibited by the antibody even though these two mutations are conformationally proximal to the universal epitope. Collectively, these data suggest that this unique, highly-conserved linear sequence in viral NA is exposed sufficiently to allow access by inhibitory antibody during the course of infection; it could represent a potential target for antiviral agents and vaccine-induced immune responses against diverse strains of type B influenza virus. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cross-protection; Influenza B; Neuraminidase; Universal antibody; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 24140051     DOI: 10.1016/j.bbrc.2013.10.041

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

Review 1.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 2.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

3.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

4.  Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study.

Authors:  Marie-Clotilde Bernard; Joanna Waldock; Sylvie Commandeur; Lea Strauß; Claudia Maria Trombetta; Serena Marchi; Fan Zhou; Serge van de Witte; Peter van Amsterdam; Sammy Ho; Katja Hoschler; Vladimir Lugovtsev; Jerry P Weir; Emanuele Montomoli; Rebecca J Cox; Othmar G Engelhardt; Damien Friel; Ralf Wagner; Thierry Ollinger; Sophie Germain; Hanna Sediri-Schön
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 5.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

6.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.

Authors:  Jason R Wilson; Jessica A Belser; Juliana DaSilva; Zhu Guo; Xiangjie Sun; Shane Gansebom; Yaohui Bai; Thomas J Stark; Jessie Chang; Paul Carney; Min Z Levine; John Barnes; James Stevens; Taronna R Maines; Terrence M Tumpey; Ian A York
Journal:  Virology       Date:  2017-09-06       Impact factor: 3.616

7.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.

Authors:  Jason R Wilson; Zhu Guo; Adrian Reber; Ram P Kamal; Nedzad Music; Shane Gansebom; Yaohui Bai; Min Levine; Paul Carney; Wen-Pin Tzeng; James Stevens; Ian A York
Journal:  Antiviral Res       Date:  2016-10-03       Impact factor: 5.970

8.  Broadly protective human antibodies that target the active site of influenza virus neuraminidase.

Authors:  Daniel Stadlbauer; Xueyong Zhu; Meagan McMahon; Jackson S Turner; Teddy J Wohlbold; Aaron J Schmitz; Shirin Strohmeier; Wenli Yu; Raffael Nachbagauer; Philip A Mudd; Ian A Wilson; Ali H Ellebedy; Florian Krammer
Journal:  Science       Date:  2019-10-25       Impact factor: 47.728

Review 9.  Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?

Authors:  Jessica Tan; Guha Asthagiri Arunkumar; Florian Krammer
Journal:  Curr Opin Immunol       Date:  2018-04-17       Impact factor: 7.486

10.  Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.

Authors:  Hongquan Wan; Hua Yang; David A Shore; Rebecca J Garten; Laura Couzens; Jin Gao; Lianlian Jiang; Paul J Carney; Julie Villanueva; James Stevens; Maryna C Eichelberger
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.